6-(Het)aryl-7-deazapurine ribonucleosides as novel potent cytostatic agents

Journal of Medicinal Chemistry

Volumn 53, Issue 1, 2010, Pages 460-470

  Nauš, Petr ^a   Pohl, Radek ^a   Votruba, Ivan ^a   Džubák, Petr ^b   Hajdúch, Marián ^b   Ameral, Ria ^c   Birkuš, Gabriel ^c   Wang, Ting ^c   Ray, Adrian S ^c   Mackman, Richard ^c   Cihlar, Tomas ^c   Hocek, Michal ^a  

^a INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY   (Czech Republic)

^b PALACKÝ UNIVERSITY   (Czech Republic)

^c GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 CHLORO (7 HALOGENATED) 7 DEAZAPURINE RIBONUCLEOSIDE DERIVATIVE; 6 FURYL 7 DEAZAPURINE DERIVATIVE; 6 THIENYL 7 DEAZAPURINE DERIVATIVE; 7 DEAZAPURINE RIBONUCLEOSIDE DERIVATIVE; 7 FLUORO 7 DEAZAPURINE RIBONUCLEOSIDE DERIVATIVE; ALKYL GROUP; ARYL GROUP; BORONIC ACID DERIVATIVE; CLOFARABINE; CYTOSTATIC AGENT; FUNCTIONAL GROUP; HETARYL GROUP; ORGANOMETALLIC COMPOUND; PALLADIUM; PHOSPHATE; RNA; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE; CELL GROWTH; CELL LINE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSS COUPLING REACTION; CYTOSTASIS; CYTOTOXICITY; DEPROTECTION REACTION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; GEOMETRY; GROWTH INHIBITION; HUMAN; HUMAN CELL; PROTEIN PHOSPHORYLATION; RNA SYNTHESIS;

ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOSTATIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MOLECULAR STRUCTURE; PURINES; RIBONUCLEOSIDES; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 74849125315     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm901428k     Document Type: Article

References (56)

1. Johnson, S. A.; Thomas, W. Therapeutic potential of purine analogue combinations in the treatment of lymphoid malignancies. Hematol. Oncol. 2000, 18, 141-153.
2. (b) Johnson, S. A. Nucleoside analogues in the treatment of haematological malignancies. Expert Opin. Pharmacother. 2001, 2, 929-943.
3. (c) Parker, W. B.; Secrist, J. A., III; Waud, W. R. Purine nucleoside antimetabolites in development for the treatment of cancer. Curr. Opin. Investig. Drugs 2004, 5, 592-596.
4. (a) Galmarini, C. M.; Mackey, J. R.; Dumontet, C. Nucleoside analogues and nucleobases in cancer treatment. Lancet Oncol. 2002, 3, 415-242.
5. (b) Galmarini, C. M.; Popowycz, F.; Joseph, B. Cytotoxic nucleoside analogues: diffreent strategies to improve their clinical afficacy. Curr. Med. Chem. 2008, 15, 1072-1082.
6. (a) Robins, R. K.; Revankar, G. R. Purine analogs and related nucleosides and nucleotides as antitumor agents. Med. Res. Rev. 1985, 5, 273-296.
7. (b) Plunkett, W.; Saunders, P. P. Metabolism and action of purine nucleoside analogs. Pharmacol. Ther. 1991, 49, 239-268.
8. (c) Robak, T.; Korycka, A.; Kasznicki, M.; Wrzesien-Kus, A.; Smolewski, P. Purine nucleoside analogues for the treatment of hematological malignancies: pharmacology and clinical applications. Curr. Cancer Drug Targets 2005, 5, 421-444.
9. (d) Jordheim, L.; Galmarini, C. M.; Dumontet, C. Drug resistance to cytotoxic nucleoside analogues. Curr. Drug Targets 2003, 4, 443-460.
10. (e) Jordheim, L. P.; Galmarini, C. M.; Dumontet, C. Recent developments to improve the efficacy of cytotoxic nucleoside analogues. Recent Pat. Anti-Cancer Drug Discovery 2006, 1, 163-170.
11. (f) Parker, W. B. Enzymology of Purine and Pyrimidine Antimetabolites Used in the Treatment of Cancer. Chem. Rev. 2009, 109, 2880-2893.
12. (a) Koch, U.; Narjes, F. Recent progress in the development of inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. Curr. Top. Med. Chem. 2007, 7, 1302-1329.
13. (b) Zapf, C. W.; Bloom, J. D.; Levin, J. I. Chapter 18 Recent Progress on Novel HCV Inhibitors. Annu. Rep. Med. Chem. 2007, 42, 281-300.
14. (a) Hocek, M.; Holý, A.; Votruba, I.; Dvořá ková, H. Synthesis and Cytostatic Activity of Substituted 6-Phenylpurine Bases and Nucleosides: Application of the Suzuki-Miyaura Cross-Coupling Reactions of 6-Chloropurine Derivatives with Phenylboronic Acids. J. Med. Chem. 2000, 43, 1817-1825.
15. (b) Hocek, M.; Holý, A.; Votruba, I.; Dvořá ková, H. Cytostatic 6-arylpurine nucleosides III. Synthesis and structure-activity relationship study in cytostatic activity of 6-aryl-, 6-hetaryl- and 6-benzylpurine ribonucleosides. Collect. Czech. Chem. Commun. 2001, 66, 483-499.
16. Hocek, M.; Nauš, P.; Pohl, R.; Votruba, I.; Furman, P. A.; Tharnish, P. M.; Otto, M. J. Cytostatic 6-Arylpurine Nucleosides 6. SAR in Anti-HCV and Cytostatic Activity of Extended Series of 6-Hetarylpurine Ribonucleosides. J. Med. Chem. 2005, 48, 5869-5873.
17. Hocek, M.; Holý, A.; Votruba, I.; Dvořáková, H. Cytostatic 6-arylpurine nucleosides II. Synthesis of sugar-modified derivatives: 9-(2-deoxy-β-D-erythro-pentofuranosyl)-, 9-(5-deoxy-β-D- ribofuranosyl)-and 9-(2,3-dihydroxypropyl)-6-phenylpurines. Collect. Czech. Chem. Commun. 2000, 65, 1683-1697.
18. Hocek, M.; Silhár, P.; Pohl, R. Cytostatic and Antiviral 6-Arylpurine Ribonucleosides, Part 8: Synthesis and Evaluation of 6-Substituted Purine 3′-Deoxyribonucleosides. Collect. Czech. Chem. Commun. 2006, 71, 1484-1496.
19. Ding, Y.; Girardet, J.-L.; Hong, Z.; Lai, V. C. H.; An, H.; Koh, Y.-h.; Shaw, S. Z.; Zhong, W. Synthesis of 9-(2-β-C-methyl-β-D-ribofuranosyl) -6-substituted purine derivatives as inhibitors of HCVRNA replication. Bioorg. Med. Chem. Lett. 2005, 15, 709-713.
20. Fernandez, F.; Garcia-Mera, X.; Morales, M.; Rodriguez-Borges, J.; De Clercq, E. Synthesis and cytostatic activities of new 6-substituted purinylcarbonucleosides derived from indan. Synthesis 2002, 1084-1090.
21. Hocek, M.; Šilhár, P.; Shih, I.; Mabery, E.; Mackman, R. Cytostatic and Antiviral 6-Arylpurine Ribonucleosides, Part 7: Synthesis and Evaluation of 6-Substituted Purine L-Ribonucleosides. Bioorg. Med. Chem. Lett. 2006, 16, 5290-5293.
22. Hocek, M.; Holý, A.; Dvořáková, H. Cytostatic 6-arylpurine nucleosides IV. Synthesis of 2-substituted 6-phenylpurine ribonucleosides. Collect. Czech. Chem. Commun. 2002, 67, 325-335.
23. Hocek, M.; Hocková, D.; Štambaský, J. Cytostatic 6-arylpurine nucleosides V. Synthesis of 8-substituted 6-phenylpurine ribonucleosides. Collect. Czech. Chem. Commun. 2003, 68, 837-848.
24. Bambuch, V.; Pohl, R.; Hocek, M. Synthesis of 6-(4,5-dihydrofuran-2-yl)- and 6-(tetrahydrofuran-2-yl)purine bases and nucleosides. Eur. J. Org. Chem. 2008, 2783-2788.
25. Kimoto, M.; Moriyama, K.; Yokoyama, S.; Hirao, I. Cytostatic evaluations of nucleoside analogs related to unnatural base pairs for a genetic expansion system. Bioorg. Med. Chem. Lett. 2007, 17, 5582-5585.
26. Nauš, P.; Kuchař, M.; Hocek, M. Cytostatic and Antiviral 6-Arylpurine Ribonucleosides IX: Synthesis and Evaluation of 6-Substituted 3-Deazapurine Ribonucleosides. Collect. Czech. Chem. Commun. 2008, 73, 665-678.
27. Montgomery, J. A.; Hewson, K. Analogs of 6-methyl-9β-D- ribofuranosylpurine. J. Med. Chem. 1968, 11, 48-52.
28. (a) Šilhár, P.; Pohl, R.; Votruba, I.; Hocek, M. Facile and Efficient Synthesis of 6-(Hydroxymethyl)purines. Org. Lett. 2004, 6, 3225-3228.
29. (b) Šilhár, P.; Pohl, R.; Votruba, I.; Hocek, M. Synthesis of 2-Substituted 6-(Hydroxymethyl)purine Bases and Nucleosides. Collect. Czech. Chem. Commun. 2005, 70, 1669-1695.
30. (a) Revankar G. R., Robins R. K. Heterocyclic Analogs of Purine Nucleosides and Nucleotides. In Chemistry of Nucleosides and Nucleotides; Townsend, L. B., Ed.; Plenum Press: New York/ London, 1988; Vol. 2, pp 200-246.
31. (b) Vittori, S.; Dal Ben, D.; Lambertucci, C.; Marucci, G.; Volpini, R.; Cristalli, G. Antiviral Properties of Deazaadenine Nucleoside Derivatives. Curr.Med. Chem. 2006, 13, 3529-3552.
32. (a) Anzai, K.; Nakamura, G.; Suzuki, S. A New Antibiotic, Tubercidin. J. Antibiot. 1957, 10, 201-204.
33. (b) Acs, G.; Mori, M.; Reich, E. Biological + Biochemical Properties of Analogue Antibiotic Tubercidin. Proc. Nat. Acad. Sci. U.S.A. 1964, 52, 493-501.
34. (a) Ugarkar, B. G.; DaRe, J. M.; Kopcho, J. J.; Browne, C. E., III; Schanzer, J. M.; Wiesner, J. B.; Erion, M. D. Adenosine Kinase Inhibitors. 1. Synthesis, Enzyme Inhibition, and Antiseizure Activity of 5-Iodotubercidin Analogues. J. Med. Chem. 2000, 43, 2883-2893.
35. (b) Ugarkar, B. G.; Castellino, A. J.; DaRe, J. M.; Kopcho, J. J.; Wiesner, J. B.; Schanzer, J. M.; Erion, M. D. Adenosine Kinase Iinhibitors. 2. Synthesis, Enzyme Inhibition, and Antiseizure Activity of Diaryltubercidin analogues. J. Med. Chem. 2000, 43, 2894-2905.
36. Kim, Y. A.; Sharon, A.; Chu, C. K.; Rais, R. H.; Al Safarjalani, O. N.; Naguib, F. N. M.; el Kouni, M. H. Structure-Activity Relationships of 7-Deaza-6-benzylthioinosine Analogues as Ligands of Toxoplasma gondii Adenosine Kinase. J. Med. Chem. 2008, 51, 3934-3945.
37. (a) Eldrup, A. B.; Prhavc, M.; Brooks, J.; Bhat, B.; Prakash, T. P.; Song, Q. L.; Bera, S.; Bhat, N.; Dande, P.; Cook, P. D.; Bennett, C. F.; Carroll, S. S.; Ball, R. G.; Bosserman, M.; Burlein, C.; Colwell, L. F.; Fay, J. F.; Flores, O. A.; Getty, K.; LaFemina, R. L.; Leone, J.; MacCoss, M.; McMasters, D. R.; Tomassini, J. E.; Von Langen, D.; Wolanski, B.; Olsen, D. B. Structure - activity relationship of heterobase-modified 2 ′-C-methyl ribonucleosides as inhibitors of hepatitis C virus RNA replication. J. Med. Chem. 2004, 47, 5284-5297.
38. (b) Eldrup, A. B.; Allerson, C. R.; Bennett, C. F.; Bera, S.; Bhat, B.; Bhat, N.; Bosserman, M. R.; Brooks, J.; Burlein, C.; Carroll, S. S.; Cook, P. D.; Getty, K. L.; MacCoss, M.; McMasters, D. R.; Olsen, D. B.; Prakash, T. P.; Prhavc, M.; Song, Q. L.; Tomassini, J. E.; Xia, J. Structure - activity relationship of purine ribonucleosides for inhibition of hepatitis C virus RNA-dependent RNA polymerase. J. Med. Chem. 2004, 47, 2283-2295.
39. (c) Olsen, D. B.; Eldrup, A. B.; Bartholomew, L.; Bhat, B.; Bosserman, M. R.; Ceccacci, A.; Colwell, L. F.; Fay, J. F.; Flores, O. A.; Getty, K. L.; Grobler, J. A.; LaFemina, R. L.; Markel, E. J.; Migliaccio, G.; Prhavc, M.; Stahlhut, M. W.; Tomassini, J. E.; MacCoss, M.; Hazuda, D. J.; Carroll, S. S. A 7-deazaadenosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic properties. Antimicrob. Agents Chemother. 2004, 48, 3944-3953.
40. Ramasamy, K.; Imamura, N.; Robins, R. K.; Revankar, G. R. A Facile Synthesis of Tubercidin and Related 7-Deazapurine Nucleosides via the Stereospecific Sodium-Salt Glycosylation Procedure. Tetrahedron Lett. 1987, 28, 5107-5110.
41. 15N-NMR Spectra. Helv. Chim. Acta 1988, 71, 1573-1585.
42. Wilcox, C. S.; Otoski, R. M. Stereoselective Preparations of Ribofuranosyl Chlorides and Ribofuranosyl Acetates. Solvent Effects and Stereoselectivity in the Reaction of Ribofuranosyl Acetates with Trimethylallylsilane. Tetrahedron Lett. 1986, 27, 1011-1014.
43. Reviews on cross-coupling reactions of purines: (a) Hocek, M. Syntheses of purines bearing carbon substituents in positions 2, 6 or 8 by metal- or organometal-mediated C-C bond-forming reactions. Eur. J. Org. Chem. 2003, 245-254.
44. (b) Agrofoglio, L. A.; Gillaizeau, I.; Saito, Y. Palladium-assisted routes to nucleosides. Chem. Rev. 2003, 103, 1875-1916.
45. (a) Hocek, M.; Masojídková, M.; Holý, A. Synthesis of Acyclic Nucleotide Analogues Derived from 6-Hetarylpurines via Cross-Coupling Reactions of 9-[2-(Diethoxyphosphonylmethoxy)ethyl]-6-iodopurine with Hetaryl Organometallic Reagents. Collect. Czech. Chem. Commun. 1997, 62, 136-146.
46. (b) Česnek, M.; Hocek, M.; Holý, A. Synthesis of acyclic nucleotide analogues derived from 2-amino-6-C-substituted purines via cross-coupling reactions of 2-amino-9-{2-[(diisopropoxyphosphoryl)methoxy]ethyl} -6-halopurines with diverse organometallic reagents. Collect. Czech. Chem. Commun. 2000, 65, 1357-1373.
47. (a) Western, E. C.; Daft, J. R.; Johnson, E. M.; Gannett, P. M.; Shaughnessy, K. H. Efficient One-Step Suzuki Arylation of Unprotected Halonucleosides, Using Water-Soluble palladium catalysts. J. Org. Chem. 2003, 68, 6767-6774.
48. (b) Čapek, P.; Pohl, R.; Hocek, M. Cross-coupling Reactions of Unprotected Halopurine Bases, Nucleosides, Nucleotides and Nucleoside Triphosphates with 4-Boronophenylalanine in Water. Synthesis of (Purin-8-yl)- and (Purin-6-yl)-phenylalanines. Org. Biomol. Chem. 2006, 4, 2278-2284.
49. (c) Pschierer, J.; Plenio, H. Suzuki-Miyaura and Sonogashira coupling of 6-chloropurines and -nucleosides in water. Org. Lett. 2009, 11, 2551-2554.
50. Wang, X. J.; Seth, P. P.; Ranken, R.; Swayze, E. E.; Migawa, M. T. Synthesis and Biological Activity of 5-Fluorotubercidin. Nucleosides, Nucleotides Nucleic Acids 2004, 23, 161-170.
51. Seela, F.; Ming, X. 7-Functionalized 7-deazapurine β-D and β-L-ribonucleosides related to tubercidin and 7-deazainosine: glycosylation of pyrrolo[2,3-d]pyrimidines with 1-O-acetyl-2,3,5- tri-O-benzoyl-β-D or β-L-ribofuranose. Tetrahedron 2007, 63, 9850-9861.
52. Vichai, V.; Kirtikara, K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nature Protoc. 2006, 1, 1112-1116.
53. Scudiero, D. A.; Shoemaker, R. H.; Paull, K. D.; Monks, A.; Tierney, S.; Nofziger, T. H.; Currens, M. J.; Seniff, D.; Boyd, M. R. Evaluation of a Soluble Tetrazolium/Formazan Assay for Cell Growth and Drug Sensitivity in Culture Using Human and Other Tumor Cell Lines. Cancer Res. 1988, 48, 4827-4833.
54. Vela, J. E.; Olson, L. Y.; Huang, A.; Fridland, A.; Ray, A. S. Simultaneous quantitation of the nucleotide analog adefovir, its phosphorylated anabolites and 2′-deoxyadenosine triphosphate by ion-pairing LC/MS/MS. J. Chromatogr., B Anal. Technol. Biomed. Life Sci. 2007, 848, 335-343.
55. Spacilova, L.; Dzubak, P.; Hajduch, M.; Krupkova, S.; Hradil, P.; Hlavac, J. Synthesis and cytotoxic activity of various 5-[alkoxy-(4-nitro-phenyl]- methyl]-uracils in their racemic form. Biorg. Med. Chem. Lett. 2007, 17, 6647-6650.
56. Krystof, V.; Cankar, P.; Frysova, I.; Slouka, J.; Kontopidis, G.; Dzubak, P.; Hajduch, M.; Srovnal, J.; De Azavedo, W. F.; Orsag, M.; Paprskarova, M.; Rolcik, J.; Latr, A.; Fischer, P.; Strnad, M. 4-Arylazo-3,5-diamino-1H-pyrazole CDK Inhibitors: SAR Study, Crystal Structure in Complex with CDK2, Selectivity, and Cellular Effects. J. Med. Chem. 2006, 49, 6500-6509.